These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 35706081)
21. Clinical Features of Adult COVID-19 Patients without Risk Factors before and after the Nationwide SARS-CoV-2 B.1.617.2 (Delta)-variant Outbreak in Korea: Experience from Gyeongsangnam-do. Ryu BH; Hong SI; Lim SJ; Cho Y; Hwang C; Kang H; Kim SH; Wi YM; Hong KW; Bae IG; Cho OH J Korean Med Sci; 2021 Dec; 36(49):e341. PubMed ID: 34931500 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of regdanvimab in patients with mild to moderate COVID-19: A rapid review and meta-analysis. Amani B; Amani B Br J Clin Pharmacol; 2023 Apr; 89(4):1282-1290. PubMed ID: 36717356 [TBL] [Abstract][Full Text] [Related]
23. Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection. Al-Obaidi MM; Gungor AB; Nematollahi S; Zangeneh TT; Bedrick EJ; Johnson KM; Low-Adegbija NE; Alam R; Rangan P; William Heise C; Ariyamuthu VK; Shetty A; Qannus AA; Murugapandian S; Ayvaci MMS; Anand PM; Tanriover B Open Forum Infect Dis; 2022 Jul; 9(7):ofac186. PubMed ID: 35791354 [TBL] [Abstract][Full Text] [Related]
24. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
25. Effectiveness of regdanvimab on mortality in COVID-19 infected patients on hemodialysis. Kee YK; Park HC; Yoon SJ; Yu S; Ko E; Cho A; Kim DH; Kim J; Lee YK Kidney Res Clin Pract; 2024 Jan; 43(1):111-121. PubMed ID: 38268125 [TBL] [Abstract][Full Text] [Related]
26. Effectiveness of mRNA BNT162b2 COVID-19 vaccine against SARS-CoV-2 Delta variant among elderly residents from a long-term care facility, South of France, May 2021. Sánchez Ruiz MA; Adonias G; Robaglia-Schlupp A; Rapilly F; Chabert M; Ramalli L; Reilhes O; Bruel C; Malfait P; Chaud P Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2586-2591. PubMed ID: 35442474 [TBL] [Abstract][Full Text] [Related]
27. Real World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients. Wynia MK; Beaty LE; Bennett TD; Carlson NE; Davis CB; Kwan BM; Mayer DA; Ong TC; Russell S; Steele J; Stocker HR; Wogu AF; Zane RD; Sokol RJ; Ginde AA medRxiv; 2022 Jan; ():. PubMed ID: 35043117 [TBL] [Abstract][Full Text] [Related]
28. An Outbreak of Breakthrough Infections by the SARS-CoV-2 Delta Variant in a Psychiatric Closed Ward. Wi YM; Kim SH; Peck KR J Korean Med Sci; 2022 Jan; 37(4):e28. PubMed ID: 35075827 [TBL] [Abstract][Full Text] [Related]
29. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466 [TBL] [Abstract][Full Text] [Related]
30. Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance - COVID-NET, 14 States, January-August 2021. Taylor CA; Patel K; Pham H; Whitaker M; Anglin O; Kambhampati AK; Milucky J; Chai SJ; Kirley PD; Alden NB; Armistead I; Meek J; Yousey-Hindes K; Anderson EJ; Openo KP; Teno K; Weigel A; Monroe ML; Ryan PA; Henderson J; Nunez VT; Bye E; Lynfield R; Poblete M; Smelser C; Barney GR; Spina NL; Bennett NM; Popham K; Billing LM; Shiltz E; Abdullah N; Sutton M; Schaffner W; Talbot HK; Ortega J; Price A; Garg S; Havers FP; MMWR Morb Mortal Wkly Rep; 2021 Oct; 70(43):1513-1519. PubMed ID: 34710076 [TBL] [Abstract][Full Text] [Related]
31. Real Asymptomatic SARS-CoV-2 Infection Might Be Rare: Importance of Careful Interviews and Follow-up. Jeong TH; Pak C; Ock M; Lee SH; Son JS; Jeon YJ J Korean Med Sci; 2020 Sep; 35(37):e333. PubMed ID: 32959547 [TBL] [Abstract][Full Text] [Related]
32. Real-world effectiveness of casirivimab plus indevimab in a dedicated ambulatory unit created for patients with early COVID-19 during a massive delta variant wave. Markowicz S; Trioux T; Rulquin C; Le Guillou C; Ouissa R; Loraux C; Saliege M; Roger PM Eur J Clin Microbiol Infect Dis; 2022 Aug; 41(8):1145-1149. PubMed ID: 35896762 [TBL] [Abstract][Full Text] [Related]
33. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021. Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519 [TBL] [Abstract][Full Text] [Related]
34. Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals. Jung J; Kim JY; Park H; Park S; Lim JS; Lim SY; Bae S; Lim YJ; Kim EO; Kim J; Park MS; Kim SH JAMA Netw Open; 2022 May; 5(5):e2213606. PubMed ID: 35608859 [TBL] [Abstract][Full Text] [Related]
35. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study. Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796 [TBL] [Abstract][Full Text] [Related]
36. Effects of SARS-CoV-2 Variants on Maternal Infection and Severity: A Single-Center Experience. Kosovali BD; Tezcan B; Mutlu NM Cureus; 2022 Apr; 14(4):e24201. PubMed ID: 35592191 [TBL] [Abstract][Full Text] [Related]
37. Rapid Control of a SARS-CoV-2 B.1.617.2 (Delta) Variant COVID-19 Community Outbreak: The Successful Experience in Pingtung County of Taiwan. Shy CG; Lu JH; Lin HC; Hung MN; Chang HC; Lu ML; Chao HR; Chen YS; Wang PS Int J Environ Res Public Health; 2022 Jan; 19(3):. PubMed ID: 35162443 [TBL] [Abstract][Full Text] [Related]
38. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients. Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000 [TBL] [Abstract][Full Text] [Related]
39. Monoclonal Antibody Therapy in Kidney Transplant Recipients With Delta and Omicron Variants of SARS-CoV-2: A Single-Center Case Series. Fernandes G; Devresse A; Scohy A; De Greef J; Yombi JC; Belkhir L; Darius T; Mourad M; Buemi A; Kabamba B; Goffin E; Kanaan N Kidney Med; 2022 Jun; 4(6):100470. PubMed ID: 35493029 [TBL] [Abstract][Full Text] [Related]
40. Changing Features of COVID-19: Characteristics of Infections with the SARS-CoV-2 Delta (B.1.617.2) and Alpha (B.1.1.7) Variants in Southern Italy. Loconsole D; Centrone F; Morcavallo C; Campanella S; Accogli M; Sallustio A; Peccarisi D; Stufano A; Lovreglio P; Chironna M Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835285 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]